Breaking: Carvana Boosts Outlook; Bullish View On RAPT Therapeutics
- August 09th, 2023
- 397 views
Shares of Carvana Co. (NYSE: CVNA) surged over 5% in pre-market trading following its announcement of an enhanced Q3 2023 outlook. The improvement is attributed to significant advancements in key business drivers and strong early-quarter momentum.
Specifically, Carvana has raised its Q3 adjusted EBITDA view to exceed $75 million, marking a shift from positive adjusted EBITDA.
$CVNA was trading at $47.50 in pre-market, reflecting a substantial increase of $3.49 (+7.93%).
In other news, RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company, received positive attention from Stifel as the investment banking firm initiated coverage with a Buy rating and a price target of $40.
Closing at $22.58 on Tuesday, this suggests a potential upside of $17.42 or approximately 77.03% for $RAPT, according to Stifel's assessment.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP Football League Provides Development and Opportunity for Athletes Pursuing the Next Level
March 20th, 2026March 19th, 2026How High School Graduates Can Kickstart Their Football Career
March 18th, 2026
Member Login